Abstract
Nasal drug delivery is a current drug delivery trend that is gaining attraction, especially for respiratory and central nervous system (CNS) diseases. This delivery pathway avoids the undesirable effects of systemic drug delivery, such as excessive dosing, damage to non-diseased organs, or drug destruction before reaching the therapeutic target. Inhaled drugs have been used for therapeutic and recreational purposes since ancient times. The development of modern inhalers for drug delivery has increased the use of intranasal drugs. More than ever, the development of drug-integrated intranasal formulations is extremely promising, providing hope for the treatment of diseases previously thought to be difficult to treat, such as tuberculosis or central nervous system diseases. Numerous investigations of intranasal formulations have been studied and published by pharmacologists over the years. The majority of research products are nanocapsules such as nanoparticles, micelles, liposomes, sol-gels, emulsions, and microspheres. Targeted drug formulations are created based on the features of the disease, the cell’s characteristics, the nature of the cell environment, and the biochemical barriers that the drug has to overcome. Preclinical and clinical assays of drug formulations help to determine their applicability in patients by the examination of their physicochemical properties, drug release, and pharmacokinetics. In this review, we focus on the factors that influence the nasal drug delivery, as well as drug release in the studies of tuberculosis and CNS formulations.
Keywords
- Central nervous system (CNS) diseases
- Tuberculosis
- Drug delivery system
- Targeted drug delivery
- Intranasal drug delivery
- Nanoparticles
- In vitro
- In vivo
- Clinical application
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AUC :
-
Area under the curve
- CF:
-
5(6)-Carboxyfluorescein
- Cmax:
-
Maximum drug concentration
- CNS:
-
Central nervous system
- CS:
-
Chitosan
- DDPC:
-
Dipalmitoyl phosphatidylcholine
- DH:
-
Diphenhydramine hydrochloride
- DMPC:
-
Dimilystoylphosphatidylcholine
- DOPE:
-
1,2-Dioleoyl-sn-glycero3-phosphoethanolamine
- DOTAP:
-
1,2-Dioleoyl-3-trimethylammonium-propane
- DSC:
-
Differential scanning calorimetry
- EE:
-
Encapsulation efficiency
- EPC:
-
Egg phosphatidylcholine
- FTIR:
-
Fourier-transform infrared
- HA:
-
Hyaluronic acid
- HPLC:
-
High-performance liquid chromatography
- INU/pArg:
-
Inulin/polyarginine
- LC:
-
Loading capacity
- LE:
-
Licorice extract
- MC:
-
Mannosylated chitosan
- MMDA :
-
Mass median aerodynamic diameter
- OZ:
-
Olanzapine
- PBS :
-
Phosphate-buffered solution
- PDI:
-
Polydispersity index
- PLGA:
-
Poly(lactic-co-glycolic acid)
- PVA:
-
Poly(vinyl alcohol)
- TC:
-
Thiolated chitosan
- TFM:
-
Teriflunomide
- Tmax:
-
Time required to reach maximum drug concentration
- WGA:
-
Wheat germ agglutinin
- XRD:
-
X-ray diffraction
- ZP:
-
Zeta potential
References
Abe K, Irie T, Uekama K (1995) Enhanced nasal delivery of luteinizing hormone releasing hormone agonist Buserelin by oleic acid solubilized and stabilized in Hydroxy propyl-β-Cyclodextrin. Chem Pharm Bull 43:2232–2237. https://doi.org/10.1248/cpb.43.2232
Ahmad N, Ahmad R, Alam MA et al (2018b) Retracted article: impact of Ultrasonication techniques on the preparation of novel Amiloride-Nanoemulsion used for intranasal delivery in the treatment of epilepsy. Artif Cells Nanomed Biotechnol 46:S192–S207. https://doi.org/10.1080/21691401.2018.1489826
Ahmad N, Ahmad R, Naqvi AA et al (2018a) Retracted article: intranasal delivery of quercetin-loaded Mucoadhesive Nanoemulsion for treatment of cerebral Ischaemia. Artif Cells Nanomed Biotechnol 46:717–729. https://doi.org/10.1080/21691401.2017.1337024
Alavian F, Shams N (2020) Oral and intra-nasal Administration of Nanoparticles in the cerebral ischemia treatment in animal experiments: considering its advantages and disadvantages. Curr Clin Pharmacol 15:20–29. https://doi.org/10.2174/1574884714666190704115345
Arisoy S, Sayiner O, Comoglu T et al (2020) In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharm Dev Technol 25:735–747. https://doi.org/10.1080/10837450.2020.1740257
Arora P, Sharma S, Garg S (2002) Permeability issues in nasal drug delivery. Drug Discov Today 7:967–975. https://doi.org/10.1016/S1359-6446(02)02452-2
Bakke H, Samdal HH, Holst J et al (2006) Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand J Immunol 63:223–231. https://doi.org/10.1111/j.1365-3083.2006.01730.x
Ballabh P, Braun A, Nedergaard M (2004) The blood–brain barrier: an overview. Neurobiol Dis 16:1–13. https://doi.org/10.1016/j.nbd.2003.12.016
Ballantine HT, Bell E, Manlapaz J (1960) Progress and problems in the neurological applications of focused ultrasound. J Neurosurg 17:858–876. https://doi.org/10.3171/jns.1960.17.5.0858
Bologa A, Bologa A (2001) Electrohydrodynamic instability of droplets as an influencing factor for aerosol space charge generation. J Electrost 51–52:470–475. https://doi.org/10.1016/S0304-3886(01)00123-1
Cornaz A-L, Buri P (1994) Nasal mucosa as an absorption barrier. Eur J Pharm Biopharm 40:261–270
Cacabelos R, Torrellas C, Fernández-Novoa L et al (2016) Histamine and immune biomarkers in CNS disorders. Mediat Inflamm 2016:1–10. https://doi.org/10.1155/2016/1924603
Cassano R, Servidio C, Trombino S (2021) Biomaterials for drugs nose–brain transport: a new therapeutic approach for neurological diseases. Materials 14:1802. https://doi.org/10.3390/ma14071802
Corbo DC, Liu J, Chien YW (1989) Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res 06:848–852. https://doi.org/10.1023/A:1015952320372
Corbo DC, Liu J-C, Chienx YW (1990) Characterization of the barrier properties of mucosal membranes. J Pharm Sci 79:202–206. https://doi.org/10.1002/jps.2600790304
Costa CP, Moreira JN, Sousa Lobo JM et al (2021) Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and Nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B 11:925–940. https://doi.org/10.1016/j.apsb.2021.02.012
Costantino HR, Illum L, Brandt G et al (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24. https://doi.org/10.1016/j.ijpharm.2007.03.025
Cunha S, Costa CP, Loureiro JA et al (2020) Double optimization of Rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutics 12:599. https://doi.org/10.3390/pharmaceutics12070599
Dahl AR, Lewis JL (1993) Respiratory tract uptake of inhalants and metabolism of Xenobiotics. Annu Rev Pharmacol Toxicol 33:383–407. https://doi.org/10.1146/annurev.pa.33.040193.002123
Danaei M, Dehghankhold M, Ataei S et al (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10:57. https://doi.org/10.3390/pharmaceutics10020057
Daniel TM (2006) The history of tuberculosis. Respir Med 100:1862–1870. https://doi.org/10.1016/j.rmed.2006.08.006
Das S, Ng WK, Tan RBH (2012) Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of Clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 47:139–151. https://doi.org/10.1016/j.ejps.2012.05.010
Diego-González L, Crecente-Campo J, Paul MJ et al (2020) Design of polymeric Nanocapsules for intranasal vaccination against mycobacterium tuberculosis: influence of the polymeric Shell and antigen positioning. Pharmaceutics 12:489. https://doi.org/10.3390/pharmaceutics12060489
Djupesland PG, Skatvedt O, Borgersen AK (2001) Dichotomous physiological effects of nocturnal external nasal dilation in heavy snorers: the answer to a Rhinologic controversy? Am J Rhinol 15:95–104. https://doi.org/10.2500/105065801781543745
Dolovich MB, Dhand R (2011) Aerosol drug delivery: developments in device design and clinical use. Lancet 377:1032–1045. https://doi.org/10.1016/S0140-6736(10)60926-9
Erdő F, Bors LA, Farkas D et al (2018) Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 143:155–170. https://doi.org/10.1016/j.brainresbull.2018.10.009
Farnoud A, Baumann I, Rashidi MM et al (2020) Simulation of patient-specific bi-directional pulsating nasal aerosol dispersion and deposition with clockwise 45° and 90° nosepieces. Comput Biol Med 123:103816. https://doi.org/10.1016/j.compbiomed.2020.103816
Finlay WH, Darquenne C (2020) Particle size distributions. J Aerosol Med Pulm Drug Deliv 33:178–180. https://doi.org/10.1089/jamp.2020.29028.whf
Gadhave DG, Kokare CR (2019) Nanostructured lipid carriers engineered for intranasal delivery of Teriflunomide in multiple sclerosis: optimization and in vivo studies. Drug Dev Ind Pharm 45:839–851. https://doi.org/10.1080/03639045.2019.1576724
Galvin P, Thompson D, Ryan KB et al (2012) Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cell Mol Life Sci 69:389–404. https://doi.org/10.1007/s00018-011-0856-6
Gholizadeh H, Ong HX, Bradbury P et al (2021) Real-time quantitative monitoring of in vitro nasal drug delivery by a nasal epithelial mucosa-on-a-chip model. Expert Opin Drug Deliv 18:803–818. https://doi.org/10.1080/17425247.2021.1873274
Gibson RE, Olanoff LS (1987) Physicochemical determinants of nasal drug absorption. J Control Release 6:361–366. https://doi.org/10.1016/0168-3659(87)90089-7
Gupta S, Dhanda S, Sandhir R (2019) Anatomy and physiology of blood-brain barrier. In: Brain targeted drug delivery system. Elsevier, pp 7–31
Häfeli UO (2004) Magnetically modulated therapeutic systems. Int J Pharm 277:19–24. https://doi.org/10.1016/j.ijpharm.2003.03.002
Haider M, Abdin SM, Kamal L et al (2020) Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics 12:288. https://doi.org/10.3390/pharmaceutics12030288
Huang CH, Kimura R, Nassar RB et al (1985) Mechanism of nasal absorption of drugs I: physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J Pharm Sci 74:608–611. https://doi.org/10.1002/jps.2600740605
Ignjatović J, Šušteršič T, Bodić A et al (2021) Comparative assessment of in vitro and in Silico methods for aerodynamic characterization of powders for inhalation. Pharmaceutics 13:1831. https://doi.org/10.3390/pharmaceutics13111831
Illum L (2010) Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3–17. https://doi.org/10.1211/0022357022539
Ishikawa F, Katsura M, Tamai I et al (2001) Improved nasal bioavailability of Elcatonin by insoluble powder formulation. Int J Pharm 224:105–114. https://doi.org/10.1016/S0378-5173(01)00736-0
Iwanaga K, Matsumoto S, Morimoto K et al (2000) Usefulness of liposomes as an intranasal dosage formulation for topical drug application. Biol Pharm Bull 23:323–326. https://doi.org/10.1248/bpb.23.323
Jadhav K, Gambhire M, Shaikh I et al (2007) Nasal drug delivery system-factors affecting and applications. Curr Drug Ther 2:27–38. https://doi.org/10.2174/157488507779422374
Kaliner M, Marom Z, Patow C et al (1984) Human respiratory mucus. J Allergy Clin Immunol 73:318–323. https://doi.org/10.1016/0091-6749(84)90403-2
Khosa A, Reddi S, Saha RN (2018) Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 103:598–613. https://doi.org/10.1016/j.biopha.2018.04.055
Krishnamoorthy R, Mitra AK (1998) Prodrugs for Nasal drug delivery. Adv Drug Deliv Rev 29:135–146. https://doi.org/10.1016/S0169-409X(97)00065-3
Lansley AB (1993) Mucociliary clearance and drug delivery via the respiratory tract. Adv Drug Deliv Rev 11:299–327. https://doi.org/10.1016/0169-409X(93)90014-U
Liu Y-L, Chen D, Shang P et al (2019) A review of magnet systems for targeted drug delivery. J Control Release 302:90–104. https://doi.org/10.1016/j.jconrel.2019.03.031
Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64:614–628. https://doi.org/10.1016/j.addr.2011.11.002
Marttin E, Schipper NGM, Verhoef JC et al (1998) Nasal Mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29:13–38. https://doi.org/10.1016/S0169-409X(97)00059-8
Mazlan MKN, Mohd Tazizi MHD, Ahmad R et al (2021) Antituberculosis targeted drug delivery as a potential future treatment approach. Antibiotics 10:908. https://doi.org/10.3390/antibiotics10080908
Meibohm B (2006) The role of pharmacokinetics and pharmacodynamics in the development of biotech drugs. In: Pharmacokinetics and pharmacodynamics of biotech drugs. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, pp 1–13
Keller L-A, Merkel O, Popp A (2022) Intranasal drug delivery: opportunities and Toxicologic challenges during drug development. Drug Deliv Transl Res 12:735–757. https://doi.org/10.1007/s13346-020-00891-5
Mittal D, Ali A, Md S et al (2014) Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv 21:75–86. https://doi.org/10.3109/10717544.2013.838713
Moffa A, Costantino A, Rinaldi V et al (2019) Nasal delivery devices: a comparative study on cadaver model. Biomed Res Int 2019:1–6. https://doi.org/10.1155/2019/4602651
Mortazavi SA, Smart JD (2011) Factors influencing gel-strengthening at the Mucoadhesive-mucus Interface. J Pharm Pharmacol 46:86–90. https://doi.org/10.1111/j.2042-7158.1994.tb03746.x
Mukhtar M, Szakonyi Z, Farkas Á et al (2021) Freeze-dried vs spray-dried Nanoplex DPIs based on chitosan and its derivatives conjugated with hyaluronic acid for tuberculosis: in vitro aerodynamic and in Silico deposition profiles. Eur Polym J 160:110775. https://doi.org/10.1016/j.eurpolymj.2021.110775
Mygind N, Thomsen J (1976) Diurnal variation of nasal protein concentration. Acta Otolaryngol 82:219–221. https://doi.org/10.3109/00016487609120888
Najafi A, Ghazvini K, Sankian M et al (2021) T helper type 1 biased immune responses by PPE17 loaded Core-Shell alginate-chitosan nanoparticles after subcutaneous and intranasal administration. Life Sci 282:119806. https://doi.org/10.1016/j.lfs.2021.119806
Nervous System Diseases. Available online: https://www.healthdirect.gov.au/nervous-system-diseases. Accessed on 3 June 2022
Ohwaki T, Ando H, Kakimoto F et al (1987) Effects of dose, PH, and Osmolarity on nasal absorption of secretin in rats II: histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of Ph and Osmolarity. J Pharm Sci 76:695–698. https://doi.org/10.1002/jps.2600760905
Ohwaki T, Ando H, Watanabe S et al (1985) Effects of dose, PH, and Osmolarity on nasal absorption of secretin in rats. J Pharm Sci 74:550–552. https://doi.org/10.1002/jps.2600740511
Ohwaki T, Ishii M, Aok S et al (1989) Effect of dose, PH, and Osmolarity on Nasal absorption of secretin in rats: III: In Vitro membrane permeation test and determination of apparent partition coefficient of secretin. Chem Pharm Bull 37:3359–3362. https://doi.org/10.1248/cpb.37.3359
Pardeshi CV, Belgamwar VS (2013) Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 10:957–972. https://doi.org/10.1517/17425247.2013.790887
Pardeshi CV, Belgamwar VS (2020) Improved brain pharmacokinetics following intranasal Administration of N,N,N-Trimethyl chitosan tailored Mucoadhesive NLCs. Mater Technol 35:249–266. https://doi.org/10.1080/10667857.2019.1674522
Park J-S, Oh Y-K, Yoon H et al (2002) In situ gelling and Mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA. J Biomed Mater Res 59:144–151. https://doi.org/10.1002/jbm.1227
Passàli D, Bellussi L (1988) Circadian changes in the secretory activity of nasal mucosa. Acta Otolaryngol 106:281–285. https://doi.org/10.3109/00016488809106437
Patel RS, McGarry GW (2001) Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required. J Lar Otol 115:633–635. https://doi.org/10.1258/0022215011908694
Pires A, Fortuna A, Alves G et al (2009) Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 12:288. https://doi.org/10.18433/J3NC79
Pires PC, Santos AO (2018) Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release 270:89–100. https://doi.org/10.1016/j.jconrel.2017.11.047
Rosada RS, Torre LG, Frantz FG et al (2008) Protection against tuberculosis by a single intranasal administration of DNA-Hsp65 vaccine complexed with cationic liposomes. BMC Immunol 9:38. https://doi.org/10.1186/1471-2172-9-38
Rutkowska E, Paja̧k K, Jóźwiak K (2013) Lipophilicity–methods of determination and its role in medicinal chemistry. Acta Pol Pharm 70(1):3–18
Sabir F, Ismail R, Csoka I (2020) Nose-to-brain delivery of Antiglioblastoma drugs embedded into lipid Nanocarrier systems: status quo and outlook. Drug Discov Today 25:185–194. https://doi.org/10.1016/j.drudis.2019.10.005
Sakane T, Akizuki M, Yamashita S et al (1991) The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the Lipophilicity of the drug. Chem Pharm Bull 39:2456–2458. https://doi.org/10.1248/cpb.39.2456
Schaefer ML, Böttger B, Silver WL et al (2002) Trigeminal collaterals in the nasal epithelium and olfactory bulb: a potential route for direct modulation of olfactory information by trigeminal stimuli. J Comp Neurol 444:221–226. https://doi.org/10.1002/cne.10143
Seju U, Kumar A, Sawant KK (2011) Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 7:4169–4176. https://doi.org/10.1016/j.actbio.2011.07.025
Si Y, Tian Q, Zhao F et al (2020) Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T H 17 responses. Sci Adv 6(32):eaba0995. https://doi.org/10.1126/sciadv.aba0995
Simonato M, Bennett J, Boulis NM et al (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:277–291. https://doi.org/10.1038/nrneurol.2013.56
Suman JD (2013) Current understanding of nasal morphology and physiology as a drug delivery target. Drug Deliv Transl Res 3:4–15. https://doi.org/10.1007/s13346-012-0121-z
Anne Trafton (2009) Targeting tumors using tiny gold particles. https://news.mit.edu/2009/gold-cancer-0504. Accessed on 11 August 2022
Ugwoke MI, Verbeke N, Kinget R (2010) The biopharmaceutical aspects of nasal Mucoadhesive drug delivery. J Pharm Pharmacol 53:3–21. https://doi.org/10.1211/0022357011775145
Vaquié A, Sauvain A, Duman M et al (2019) Injured axons instruct Schwann cells to build constricting actin spheres to accelerate axonal disintegration. Cell Rep 27:3152–3166.e7. https://doi.org/10.1016/j.celrep.2019.05.060
Vasir J, Reddy M, Labhasetwar V (2005) Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 1:47–64. https://doi.org/10.2174/1573413052953110
Vishwa B, Moin A, Gowda DV et al (2021) Pulmonary targeting of inhalable Moxifloxacin microspheres for effective Management of Tuberculosis. Pharmaceutics 13:79. https://doi.org/10.3390/pharmaceutics13010079
Viswanathan V, Pharande R, Bannalikar A et al (2019) Inhalable liposomes of Glycyrrhiza Glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo Pharmacodynamic studies. Drug Dev Ind Pharm 45:11–20. https://doi.org/10.1080/03639045.2018.1513025
Wofford MR, Kimbell JS, Frank-Ito DO et al (2015) Computational study of functional endoscopic sinus surgery and maxillary sinus drug delivery. Rhinology 53:41–49. https://doi.org/10.4193/Rhin13.065
Xi J, Si XA, Peters S et al (2017) Understanding the mechanisms underlying pulsating aerosol delivery to the maxillary sinus: in vitro tests and computational simulations. Int J Pharm 520:254–266. https://doi.org/10.1016/j.ijpharm.2017.02.017
Xi J, Zhang Z, Si X (2015) Improving intranasal delivery of neurological Nanomedicine to the olfactory region using Magnetophoretic guidance of microsphere carriers. Int J Nanomedicine 2015(10):1211. https://doi.org/10.2147/IJN.S77520
Yang C, Mitra AK (2001) Nasal absorption of tyrosine-linked model compounds. J Pharm Sci 90:340–347. https://doi.org/10.1002/1520-6017(200103)90:3<340:AID-JPS9>3.0.CO;2-F
Youssef NAHA, Kassem AA, Farid RM et al (2018) A novel nasal Almotriptan loaded solid lipid nanoparticles in Mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm 548:609–624. https://doi.org/10.1016/j.ijpharm.2018.07.014
Zumla A, Raviglione M, Hafner R et al (2013) Tuberculosis. N Engl J Med 368:745–755. https://doi.org/10.1056/NEJMra1200894
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nhung Vu, T.H., Morozkina, S., Snetkov, P., Uspenskaya, M. (2023). Nasal Drug Delivery Systems for the Treatment of Diseases of the Central Nervous System and Tuberculosis. In: Lamprou, D. (eds) Nano- and Microfabrication Techniques in Drug Delivery . Advanced Clinical Pharmacy - Research, Development and Practical Applications, vol 2. Springer, Cham. https://doi.org/10.1007/978-3-031-26908-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-031-26908-0_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-26907-3
Online ISBN: 978-3-031-26908-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)